AstraZeneca’s asthma drug Fasenra looks promising for a set of rare chronic immune diseases
Just 16 months after the FDA approved AstraZeneca’s Fasenra for a severe form of asthma, investigators at the NIH have found that the drug appears …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
